Lupin Secures U.S. FDA Approval for Prucalopride Tablets, Eyes $184 Million Gastrointestinal Drug Market

Mumbai, 25 June 2025: Lupin Ltd (NSE: LUPIN | BSE: 500257) has received final approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) concerning Prucalopride Tablets in strengths of 1 mg and 2 mg. The approved product is a generic version of Motegrity®, a drug originally developed by Takeda Pharmaceuticals U.S.A. Inc.

As of 1:55 PM IST on 25 June, shares of Lupin Ltd were trading marginally higher at ₹1,934.60, reflecting a gain of ₹3.80 or 0.20% for the day. The stock opened at ₹1,940.00 and touched an intraday high of ₹1,953.00, before dipping to a low of ₹1,923.50. The market capitalisation stood at ₹88.35K crore with a P/E ratio of 26.99. The modest uptick follows the company’s announcement of securing U.S. FDA approval for Prucalopride Tablets, targeting a $184 million market.

Product Scope and Market Opportunity

The FDA-approved tablets are intended for the treatment of chronic idiopathic constipation (CIC) in adults—a condition for which Prucalopride acts as a serotonin-4 (5-HT4) receptor agonist, designed to stimulate colonic motility and help restore bowel regularity.

Lupin will manufacture the newly approved tablets at its Goa-based facility in India. According to data from IQVIA MAT (April 2025), the annual U.S. market for Motegrity® was valued at $184 million, offering Lupin a significant opportunity in the gastrointestinal therapeutics segment.

Strategic Milestone for U.S. Expansion

Approval under the ANDA framework confirms the bioequivalence of Lupin’s version to the Reference Listed Drug (RLD) and permits the company to commence U.S. commercialisation, subject to applicable patent protections and exclusivity rights.

This regulatory milestone reinforces Lupin’s ongoing focus on complex generics and differentiated therapies, especially within high-potential therapeutic areas like GI and CNS. The FDA clearance is also expected to strengthen its presence in the high-margin U.S. generics market, which remains central to the company’s growth strategy.

Corporate Snapshot: Lupin at a Glance

Headquartered in Mumbai, Lupin is a globally active pharmaceutical player with a commercial footprint across more than 100 countries. It operates 15 manufacturing facilities and seven R&D centres, supported by a workforce exceeding 23,000 professionals.

The company holds established leadership across therapeutic areas such as respiratory, cardiovascular, anti-diabetic, CNS, gastrointestinal, and women’s health. Its ecosystem includes verticals like Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, reflecting its integrated approach to healthcare delivery.

What’s Next: Competitive Positioning and Pipeline Prospects

The approval for Prucalopride further consolidates Lupin’s U.S. product basket, which has seen a steady expansion with multiple FDA clearances in the past year. Earlier in 2025, Lupin also secured approvals for generic Lurasidone tablets and Budesonide inhalers, both contributing to its central nervous system and respiratory therapy portfolios, respectively.

Moreover, the company is known to be working on a pipeline of 20+ complex generics, including injectable and inhalation therapies, which are expected to contribute materially to revenues over the next 2–3 years. With increasing pricing pressures in the generics space, differentiation through technology and therapeutic focus has become key—a strategy Lupin appears to be executing with precision.

Conclusion

 Lupin’s FDA nod for Prucalopride not only opens the doors to a $184 million addressable market but also underscores the company’s intent to scale its complex generics footprint in the U.S. The milestone is well-aligned with its broader growth ambitions, offering both near-term revenue visibility and long-term portfolio depth. With U.S. launches likely to gather pace in the second half of 2025, investor and market attention will now turn to commercial execution and pricing dynamics in a competitive yet opportunity-rich therapeutic space.

Prucalopride is marketed under the brand name Motegrity® by Takeda Pharmaceuticals U.S.A. Inc., a registered trademark.

REF: https://nsearchives.nseindia.com/corporate/Lupin2_25062025122646_NSELetterwithPressRelease25062025.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations